Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Daiichi Sankyo
Argus Health
Harvard Business School
UBS
Cantor Fitzgerald

Generated: May 20, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,949,527

« Back to Dashboard

Which drugs does patent 6,949,527 protect, and when does it expire?

Patent 6,949,527 protects BRIDION and is included in one NDA.

This patent has forty-two patent family members in thirty countries.

Summary for Patent: 6,949,527
Title: 6-Mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
Abstract:Disclosed is a 6-mercapto-cyclodextrin derivative having a general formula (I, ) wherein m is 0-7 and n is 1-8 and m+n=7 or 8; R is (C.sub.1-6) alkylene, optionally substituted with 1-3 OH groups, or (CH.sub.2).sub.o -phenylene-CH.sub.2).sub.p --; o and p are independently 0-4; X is COOH, CONHR.sub.3, NHCOR.sub.2, SO.sub.2 OH, PO(OH).sub.2, O(CH.sub.2 --CH.sub.2 --O).sub.q --H, OH or tetrazol-5-yl: R.sub.2 is H or (C.sub.1-3)alkyl; R.sub.2 is carboxyphenyl; q is 1-3; or pharmaceutically acceptable salts thereof. The 6-mercaptocyclodextrin derivative is highly suitable for use in the reversal of drug-induced neuromuscular block.
Inventor(s): Zhang; Mingqiang (Montreal, CA), Palin; Ronald (Near Kilsyth, GB), Bennett; David Jonathan (Edinburgh, GB)
Assignee: Akzo Nobel N.V. (Arnhem, NL)
Application Number:10/603,355
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 6,949,527
Patent Claim Types:
see list of patent claims
Compound; Device; Use;

Drugs Protected by US Patent 6,949,527

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Organon Sub Merck BRIDION sugammadex sodium SOLUTION;INTRAVENOUS 022225-002 Dec 15, 2015 RX Yes No ➤ Sign Up ➤ Sign Up REVERSAL OF NEUROMUSCULAR BLOCKAGE INDUCED BY ROCURONIUM BROMIDE OR VECURONIUM BROMIDE ➤ Sign Up
Organon Sub Merck BRIDION sugammadex sodium SOLUTION;INTRAVENOUS 022225-001 Dec 15, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up REVERSAL OF NEUROMUSCULAR BLOCKAGE INDUCED BY ROCURONIUM BROMIDE OR VECURONIUM BROMIDE ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,949,527

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
99309558Nov 29, 1999

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Farmers Insurance
Queensland Health
Chubb
Harvard Business School
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.